OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
WALTHAM, Mass., April 27, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Deutsche Bank Annual Health Care Conference
Tuesday, May 8, 2018 at 8:40 a.m. ET
Location: Boston, MA - Bank of America Merrill Lynch Health Care Conference
Tuesday, May 15, 2018 at 4:20 p.m. PT (7:20 p.m. ET)
Location: Las Vegas, NV
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
